Gilead Sciences (GILD) 89.85 $GILD
1 Hidden Blockbuster Lurking in Merck's Pipeline?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 4:00PM CDT
Merck already markets Isentress, one of the most widely used medications for the treatment of HIV, but it has another drug in its pipeline that may also become a blockbuster someday, too. Doravirine, also known as MK-1439, is currently in...
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Mon Jul 14, 3:47PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Jul 14, 3:46PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Mon Jul 14, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Early Glance: Biotechnology companies
AP - Mon Jul 14, 9:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $89.72
Comtex SmarTrend(R) - Mon Jul 14, 9:04AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $88.99 today and have reached the first resistance level of $89.72. Should the shares continue to rise, the resistance pivots of $90.72 and $92.45 will be of interest.
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver
PR Newswire - Mon Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SUNE, TWTR, GILD, DRI, and BLK.
Obamacare's Surprising HIV Drug Demand
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 13, 1:01PM CDT
The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV. As a result, Express Scripts has reported that...
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Senate grills Gilead on price
at Investor's Business Daily - Fri Jul 11, 5:47PM CDT
The chairman and a senior member of the Senate Finance Committee questioned the biotech in a letter addressed to the CEO about how it prices its blockbuster hepatitis C drug Sovaldi. The hep C treatment costs $1,000 per pill. In March, the House...
France Not Retreating from Gilead Sciences
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jul 11, 4:01PM CDT
Gilead Sciences has been no stranger to controversy, with complaints about the pricing of its hepatitis c therapy Sovaldi coming in from every corner. Even with the drug's massive market success so far ($2.3 billion in sales in its first full...
1 Drug More Important to Gilead Than Sovaldi
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 11, 4:00PM CDT
Gilead 's Sovaldi roared out of the gate following its FDA approval in December. Sales of the drug totaled more than $2.2 billion in its first quarter on the market, making it the fastest drug to ever reach billion-dollar blockbuster status, and one...
Stocks Mixed In Low-Volume Session; Facebook Firms Up
at Investor's Business Daily - Fri Jul 11, 11:05AM CDT
Major averages traded mixed and mostly unchanged Thursday just over two hours into the session. The Nasdaq added 0.1% while the Dow Jones industrial average and S&P 500 each slipped 0.1%. Volume on the NYSE and Nasdaq was tracking sharply lower than...
Senators Ask Gilead To Explain Sovaldi Pricing
at Investor's Business Daily - Fri Jul 11, 10:35AM CDT
The chairman and a senior member of the U.S. Senate Finance Committee on Friday issued a battery of questions to Gilead Sciences (GILD) about how it priced its blockbuster hepatitis C drug Sovaldi, adding to the chorus of objections to the product's...
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Gilead Sciences Has Returned 22.4% Since SmarTrend Recommendation (GILD)
Comtex SmarTrend(R) - Thu Jul 10, 11:11AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 22.36% as of today's recent price of $88.78.
1 Hidden Blockbuster Lurking in Merck's Pipeline?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 14, 4:00PM CDT
Merck already markets Isentress, one of the most widely used medications for the treatment of HIV, but it has another drug in its pipeline that may also become a blockbuster someday, too. Doravirine, also known as MK-1439, is currently in...
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.26%
Comtex SmarTrend(R) - Mon Jul 14, 3:47PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Jul 14, 3:46PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $88.84 to a high of $90.27. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $89.98 on volume of 10.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Mon Jul 14, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Early Glance: Biotechnology companies
AP - Mon Jul 14, 9:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $89.72
Comtex SmarTrend(R) - Mon Jul 14, 9:04AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $88.99 today and have reached the first resistance level of $89.72. Should the shares continue to rise, the resistance pivots of $90.72 and $92.45 will be of interest.
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver
PR Newswire - Mon Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SUNE, TWTR, GILD, DRI, and BLK.
Obamacare's Surprising HIV Drug Demand
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 13, 1:01PM CDT
The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV. As a result, Express Scripts has reported that...
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Senate grills Gilead on price
at Investor's Business Daily - Fri Jul 11, 5:47PM CDT
The chairman and a senior member of the Senate Finance Committee questioned the biotech in a letter addressed to the CEO about how it prices its blockbuster hepatitis C drug Sovaldi. The hep C treatment costs $1,000 per pill. In March, the House...
France Not Retreating from Gilead Sciences
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jul 11, 4:01PM CDT
Gilead Sciences has been no stranger to controversy, with complaints about the pricing of its hepatitis c therapy Sovaldi coming in from every corner. Even with the drug's massive market success so far ($2.3 billion in sales in its first full...
1 Drug More Important to Gilead Than Sovaldi
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 11, 4:00PM CDT
Gilead 's Sovaldi roared out of the gate following its FDA approval in December. Sales of the drug totaled more than $2.2 billion in its first quarter on the market, making it the fastest drug to ever reach billion-dollar blockbuster status, and one...
Stocks Mixed In Low-Volume Session; Facebook Firms Up
at Investor's Business Daily - Fri Jul 11, 11:05AM CDT
Major averages traded mixed and mostly unchanged Thursday just over two hours into the session. The Nasdaq added 0.1% while the Dow Jones industrial average and S&P 500 each slipped 0.1%. Volume on the NYSE and Nasdaq was tracking sharply lower than...
Senators Ask Gilead To Explain Sovaldi Pricing
at Investor's Business Daily - Fri Jul 11, 10:35AM CDT
The chairman and a senior member of the U.S. Senate Finance Committee on Friday issued a battery of questions to Gilead Sciences (GILD) about how it priced its blockbuster hepatitis C drug Sovaldi, adding to the chorus of objections to the product's...
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Gilead Sciences Has Returned 22.4% Since SmarTrend Recommendation (GILD)
Comtex SmarTrend(R) - Thu Jul 10, 11:11AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 22.36% as of today's recent price of $88.78.
